Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression

Osimertinib, a third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is the standard treatment for patients with lung cancer harboring EGFR T790M; however, acquired resistance is inevitable due to genetic and epigenetic changes in cancer cells. In addition, a recent ran...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncol Lett
Main Authors: Nishii, Kazuya, Ohashi, Kadoaki, Watanabe, Hiromi, Makimoto, Go, Nakasuka, Takamasa, Higo, Hisao, Ninomiya, Kiichiro, Kato, Yuka, Kubo, Toshio, Rai, Kammei, Ichihara, Eiki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Format: Artigo
Jezik:Inglês
Izdano: D.A. Spandidos 2021
Teme:
Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8299008/
https://ncbi.nlm.nih.gov/pubmed/34386061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12900
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki